MyMD Pharmaceuticals, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Significant Accounting Policies (Tables)

Significant Accounting Policies (Tables)

9 Months Ended

Sep. 30, 2018

This includes basing value on yields currently available on comparable securities of issuers with similar credit ratings.

	Quoted Prices in Active Markets for Identical Assets or Liabilities (Level 1)		Quoted Prices for Similar Assets or Liabilities in Active Markets (Level 2)		Significant Unobservable Inputs (Level 3)
Marketable securities at September 30, 2018	$	-	$	4,866,033	$	-

Marketable securities at December 31, 2017	$	-	$	5,011,607	$	-

Schedule of Future Amortization Expense of Intangible Assets

The following is an annual schedule of approximate future amortization of the Company’s intangible assets:

Period	Amount
2018 (three months)	$	42,777
2019		171,108
2020		149,298
2021		147,315
2022		147,315
2023		147,315

Schedule of Anti-dilutive Securities Excluded from Computation of Earnings Per Share

The following securities are excluded from the calculation of weighted average dilutive common shares because their inclusion would have been anti-dilutive:

	For the Three and Nine Months Ended September 30,
	2018		2017
Incentive and Award Stock Options		10,500		31,875
Unvested Restricted Shares of Common Stock		-		1,146
Warrants		1,416,229		186,321
Total potentially dilutive shares		1,426,729		219,342